A4M Board Exam Prep 2026 Questions &
Correct Answers with Detailed
Rationales Graded A | Anti-Aging,
Functional Medicine & Longevity
Conquer the A4M Written Exam with this fully updated 2026 Study Guide! Master exam-style
questions with verified answers covering Endocrinology, Cardiology, Neurology,
Immunometabolism & Longevity. Go beyond memorization with detailed Rationales
on senolytics, NAD+, epigenetics, omega-3 dosing & more. Based on the latest A4M guidelines,
this QB details key hormonal pathways (DHEA, estrogen) and essential concepts like
the Hallmarks of Aging. Guaranteed to boost your test-taking confidence. Avoid the noise and
focus on what matters—secure your Diplomate status with confidence today!
,1. A 62-year-old male patient with a history of stable coronary artery disease presents with
a lipid panel showing elevated LDL particle number, small dense LDL phenotype, and low
HDL-2b subfractions. He has been adherent to a Mediterranean diet and exercises
regularly. You consider prescribing prescription-grade omega-3 fatty acids. According to
current clinical guidelines and the pharmacological actions of omega-3 therapy, which of
the following statements regarding this intervention is most accurate?
a) Krill oil should be used as the first-line source of omega-3s due to its superior
bioavailability and phospholipid content.
b) The combined daily dose of EPA and DHA should be 3 grams at a 3:2 ratio,
supplemented with gamma-tocopherol to prevent lipid peroxidation.
c) Omega-3 fatty acids primarily lower LDL particle number by increasing hepatic LDL
receptor expression and decreasing PCSK9 activity.
d) The addition of 700 mg of alpha-tocopherol per gram of EPA/DHA is required to
maintain the stability of the fatty acid bonds.
Rationale: Option B is correct because prescription omega-3 therapy for dyslipidemia
specifically requires 3 grams/day of combined EPA and DHA in a 3:2 ratio, and the
addition of gamma (not alpha) tocopherol at 700 mg per gram of DHA/EPA is
recommended to prevent oxidative degradation. Option A is incorrect because krill oil is
not currently recommended as a primary treatment for dyslipidemia. Option C is
incorrect because omega-3s do not significantly lower LDL particle number; instead, they
reduce VLDL entry, increase LDL particle size, and raise anti-atherogenic HDL-2b. Option
D is incorrect because it specifies alpha-tocopherol rather than the correct gamma/delta-
tocopherol form.
2. A 55-year-old perimenopausal woman presents with fatigue, brain fog, and mild hot
flashes. Her laboratory workup reveals a normal thyroid panel, normal fasting glucose,
and a DHEA-S level at the lower end of the reference range. She is concerned about
aging-related decline and asks about DHEA supplementation. Which of the following
statements accurately reflects the physiology and clinical considerations of DHEA in the
context of anti-aging medicine?
a) DHEA is exclusively produced in the ovaries and its primary function is to serve as a direct
agonist at estrogen receptors.
b) DHEA is synthesized in the adrenal zona reticularis and can serve as a precursor for
peripheral conversion to estrogen and testosterone.
c) Oral DHEA supplementation is contraindicated in all perimenopausal women due to
, the risk of androgenization and hirsutism.
d) DHEA levels typically increase with age, contributing to the hyperandrogenic state
seen in aging women.
Rationale: Option B is correct because DHEA (dehydroepiandrosterone) is produced primarily
in the adrenal zona reticularis and functions as a prohormone for peripheral conversion
to active androgens and estrogens in target tissues. Option A is incorrect because DHEA
is not exclusively ovarian; the adrenals are the major source, and it does not act as a
direct estrogen receptor agonist. Option C is incorrect because DHEA supplementation is
not absolutely contraindicated; it is used cautiously with monitoring for androgenic side
effects. Option D is incorrect because DHEA levels decline progressively with age, not
increase.
3. A 68-year-old male with mild cognitive impairment and a family history of Alzheimer's
disease asks about nutritional strategies to preserve brain health. Which of the following
mechanisms is most directly associated with neuroprotection in the context of a ging?
a) Increasing dietary saturated fat to support myelin synthesis.
b) Reducing chronic neuroinflammation through omega-3 fatty acids and polyphenols.
c) Exclusively using high-dose vitamin E as monotherapy for cognitive preservation.
d) Avoiding all dietary carbohydrates to prevent cerebral insulin resistance.
Rationale: Option B is correct because neuroinflammation is a key driver of neurodegenerative
disease, and omega-3s alongside polyphenols have demonstrated neuroprotective effects.
Option A is incorrect because saturated fat may exacerbate inflammation. Option C is incorrect
because high-dose vitamin E as monotherapy has not shown consistent benefit and may carry
risks. Option D is incorrect because complete carbohydrate avoidance is neither practical nor
supported by evidence.
4. A 72-year-old female with osteoarthritis and multiple comorbidities asks about senolytic
therapy after reading about it online. Which of the following best characterizes the
current evidence for senolytics in human clinical practice?
a) Senolytics have been FDA-approved for the treatment of osteoarthritis and frailty.
b) Early human trials show modest reductions in inflammatory markers with limited
functional improvement.
c) Senolytics completely eliminate all senescent cells after a single course of treatment.
d) Fisetin and quercetin are contraindicated due to severe hepatotoxicity.
, Rationale: Option B is correct because while preclinical data is promising, human trials have
demonstrated only modest effects on inflammatory biomarkers and limited gains in physical
function. Option A is incorrect because senolytics are not FDA-approved for these indications.
Option C is incorrect because senolytics reduce but do not completely eliminate senescent cells.
Option D is incorrect because fisetin and quercetin are being studied and are not categorically
contraindicated.
5. A 60-year-old male with metabolic syndrome and elevated fasting insulin is interested in
NAD+ augmentation therapy. Which of the following statements best reflects the current
clinical evidence regarding NAD+ precursors?
a) NAD+ precursors consistently improve muscle strength and cognitive function across all
human trials.
b) NAD+ precursors reliably increase circulating NAD+ levels, but improvements in durable
clinical outcomes remain inconsistent.
c) NAD+ precursors are only effective when administered intravenously.
d) NAD+ augmentation directly reverses epigenetic age by 10 years within 3 months.
Rationale: Option B is correct because NAD+ precursors do raise blood NAD+ levels, but clinical
endpoints like strength and cognition have shown variable results. Option A is incorrect because
consistency across trials has not been demonstrated. Option C is incorrect because oral
administration is common. Option D is incorrect because such rapid epigenetic reversal is not
supported by current data.
6. A 65-year-old female with low bone density and menopausal symptoms is considering
hormone therapy. Which of the following is a key advantage of transdermal over oral
estrogen administration?
a) Transdermal estrogen has a more potent effect on hepatic lipid metabolism.
b) Transdermal estrogen avoids first-pass hepatic metabolism and reduces inflammatory
markers.
c) Transdermal estrogen is always more effective for vasomotor symptom control.
d) Transdermal estrogen does not require any progestin co-administration.
Rationale: Option B is correct because transdermal administration bypasses hepatic first-pass
metabolism, which reduces the inflammatory effects associated with oral estrogen. Option A is
incorrect because oral estrogen has greater effects on hepatic proteins. Option C is incorrect
Correct Answers with Detailed
Rationales Graded A | Anti-Aging,
Functional Medicine & Longevity
Conquer the A4M Written Exam with this fully updated 2026 Study Guide! Master exam-style
questions with verified answers covering Endocrinology, Cardiology, Neurology,
Immunometabolism & Longevity. Go beyond memorization with detailed Rationales
on senolytics, NAD+, epigenetics, omega-3 dosing & more. Based on the latest A4M guidelines,
this QB details key hormonal pathways (DHEA, estrogen) and essential concepts like
the Hallmarks of Aging. Guaranteed to boost your test-taking confidence. Avoid the noise and
focus on what matters—secure your Diplomate status with confidence today!
,1. A 62-year-old male patient with a history of stable coronary artery disease presents with
a lipid panel showing elevated LDL particle number, small dense LDL phenotype, and low
HDL-2b subfractions. He has been adherent to a Mediterranean diet and exercises
regularly. You consider prescribing prescription-grade omega-3 fatty acids. According to
current clinical guidelines and the pharmacological actions of omega-3 therapy, which of
the following statements regarding this intervention is most accurate?
a) Krill oil should be used as the first-line source of omega-3s due to its superior
bioavailability and phospholipid content.
b) The combined daily dose of EPA and DHA should be 3 grams at a 3:2 ratio,
supplemented with gamma-tocopherol to prevent lipid peroxidation.
c) Omega-3 fatty acids primarily lower LDL particle number by increasing hepatic LDL
receptor expression and decreasing PCSK9 activity.
d) The addition of 700 mg of alpha-tocopherol per gram of EPA/DHA is required to
maintain the stability of the fatty acid bonds.
Rationale: Option B is correct because prescription omega-3 therapy for dyslipidemia
specifically requires 3 grams/day of combined EPA and DHA in a 3:2 ratio, and the
addition of gamma (not alpha) tocopherol at 700 mg per gram of DHA/EPA is
recommended to prevent oxidative degradation. Option A is incorrect because krill oil is
not currently recommended as a primary treatment for dyslipidemia. Option C is
incorrect because omega-3s do not significantly lower LDL particle number; instead, they
reduce VLDL entry, increase LDL particle size, and raise anti-atherogenic HDL-2b. Option
D is incorrect because it specifies alpha-tocopherol rather than the correct gamma/delta-
tocopherol form.
2. A 55-year-old perimenopausal woman presents with fatigue, brain fog, and mild hot
flashes. Her laboratory workup reveals a normal thyroid panel, normal fasting glucose,
and a DHEA-S level at the lower end of the reference range. She is concerned about
aging-related decline and asks about DHEA supplementation. Which of the following
statements accurately reflects the physiology and clinical considerations of DHEA in the
context of anti-aging medicine?
a) DHEA is exclusively produced in the ovaries and its primary function is to serve as a direct
agonist at estrogen receptors.
b) DHEA is synthesized in the adrenal zona reticularis and can serve as a precursor for
peripheral conversion to estrogen and testosterone.
c) Oral DHEA supplementation is contraindicated in all perimenopausal women due to
, the risk of androgenization and hirsutism.
d) DHEA levels typically increase with age, contributing to the hyperandrogenic state
seen in aging women.
Rationale: Option B is correct because DHEA (dehydroepiandrosterone) is produced primarily
in the adrenal zona reticularis and functions as a prohormone for peripheral conversion
to active androgens and estrogens in target tissues. Option A is incorrect because DHEA
is not exclusively ovarian; the adrenals are the major source, and it does not act as a
direct estrogen receptor agonist. Option C is incorrect because DHEA supplementation is
not absolutely contraindicated; it is used cautiously with monitoring for androgenic side
effects. Option D is incorrect because DHEA levels decline progressively with age, not
increase.
3. A 68-year-old male with mild cognitive impairment and a family history of Alzheimer's
disease asks about nutritional strategies to preserve brain health. Which of the following
mechanisms is most directly associated with neuroprotection in the context of a ging?
a) Increasing dietary saturated fat to support myelin synthesis.
b) Reducing chronic neuroinflammation through omega-3 fatty acids and polyphenols.
c) Exclusively using high-dose vitamin E as monotherapy for cognitive preservation.
d) Avoiding all dietary carbohydrates to prevent cerebral insulin resistance.
Rationale: Option B is correct because neuroinflammation is a key driver of neurodegenerative
disease, and omega-3s alongside polyphenols have demonstrated neuroprotective effects.
Option A is incorrect because saturated fat may exacerbate inflammation. Option C is incorrect
because high-dose vitamin E as monotherapy has not shown consistent benefit and may carry
risks. Option D is incorrect because complete carbohydrate avoidance is neither practical nor
supported by evidence.
4. A 72-year-old female with osteoarthritis and multiple comorbidities asks about senolytic
therapy after reading about it online. Which of the following best characterizes the
current evidence for senolytics in human clinical practice?
a) Senolytics have been FDA-approved for the treatment of osteoarthritis and frailty.
b) Early human trials show modest reductions in inflammatory markers with limited
functional improvement.
c) Senolytics completely eliminate all senescent cells after a single course of treatment.
d) Fisetin and quercetin are contraindicated due to severe hepatotoxicity.
, Rationale: Option B is correct because while preclinical data is promising, human trials have
demonstrated only modest effects on inflammatory biomarkers and limited gains in physical
function. Option A is incorrect because senolytics are not FDA-approved for these indications.
Option C is incorrect because senolytics reduce but do not completely eliminate senescent cells.
Option D is incorrect because fisetin and quercetin are being studied and are not categorically
contraindicated.
5. A 60-year-old male with metabolic syndrome and elevated fasting insulin is interested in
NAD+ augmentation therapy. Which of the following statements best reflects the current
clinical evidence regarding NAD+ precursors?
a) NAD+ precursors consistently improve muscle strength and cognitive function across all
human trials.
b) NAD+ precursors reliably increase circulating NAD+ levels, but improvements in durable
clinical outcomes remain inconsistent.
c) NAD+ precursors are only effective when administered intravenously.
d) NAD+ augmentation directly reverses epigenetic age by 10 years within 3 months.
Rationale: Option B is correct because NAD+ precursors do raise blood NAD+ levels, but clinical
endpoints like strength and cognition have shown variable results. Option A is incorrect because
consistency across trials has not been demonstrated. Option C is incorrect because oral
administration is common. Option D is incorrect because such rapid epigenetic reversal is not
supported by current data.
6. A 65-year-old female with low bone density and menopausal symptoms is considering
hormone therapy. Which of the following is a key advantage of transdermal over oral
estrogen administration?
a) Transdermal estrogen has a more potent effect on hepatic lipid metabolism.
b) Transdermal estrogen avoids first-pass hepatic metabolism and reduces inflammatory
markers.
c) Transdermal estrogen is always more effective for vasomotor symptom control.
d) Transdermal estrogen does not require any progestin co-administration.
Rationale: Option B is correct because transdermal administration bypasses hepatic first-pass
metabolism, which reduces the inflammatory effects associated with oral estrogen. Option A is
incorrect because oral estrogen has greater effects on hepatic proteins. Option C is incorrect
